Charles Schwab Investment Management Inc Allogene Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,232,535 shares of ALLO stock, worth $1.49 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,232,535
Previous 1,155,844
6.64%
Holding current value
$1.49 Million
Previous $1.69 Million
17.49%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding ALLO
# of Institutions
169Shares Held
162MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$22.6 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$19.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$13.5 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$13.4 Million3.7% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$12.7 Million0.5% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $174M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...